print header

Some changes have been made to the vaccines supplied by Ontario Government Pharmaceutical (OGP).

1. Meningococcal vaccine for High-risk Clients over age 55

  • Temporarily, Menactra® (Meningococcal-Conjugate A,C,Y,W-135) is replacing Menomune® (Meningococcal-Polysaccharide A,C,Y,W-135) for high-risk individuals over the age of 55.
  • When Menomune® vaccine becomes available again; it will be used for older high-risk adults. Menactra® is only licensed up to age 55 years.

2. DTaP-IPV vaccines: Quadracel® replaced by Infanrix®-IPV

  • Infanrix®-IPV is replacing Quadracel® permanently as an equivalent product.
  • Infanrix®-IPV is indicated only for unimmunized children ages 5 and 6, as their primary series.

3. MMRV vaccines: ProQuad™ and Priorix-Tetra®

  • ProQuad™ (new) and Priorix-Tetra® are interchangeable MMRV vaccines that will be distributed based on availability for protection against measles, mumps, rubella and varicella.
  • Priorix-Tetra® contains amino acids, lactose, mannitol, sorbitol, neomycin.
  • ProQuad™ contains gelatin and neomycin.
  • When MMRV vaccines are administered to children aged 12 to 23 months, there is a slightly higher
    risk of febrile seizures in the 5 to 12 days following vaccination in 1 of every 2,600 vaccinated children compared to individually administered MMR and varicella vaccines.
  • In Ontario, MMRV vaccine is publicly funded for children 4 to 12 years of age. MMR vaccine is given at 12 months and varicella vaccine at 15 months.
  • MMRV should be administered promptly after reconstitution.


Have questions? Call Health Connection at 705-721-7520 or 1-877-721-7520 ext. 8806.

Did you find what you were looking for today?
What did you like about this page?
How can we improve this page?

If you have any questions or concerns that require a response, please contact Health Connection directly.

Thanks for your feedback.
Failed to submit comment. Please try submitting again or contact us at the Health Unit.
Comment already submitted ...